Effect of Early Gait Training on Knee Cartilage Degeneration After Anterior Cruciate Ligament Reconstruction
Condition(s) studied
Investigational drug(s) / intervention(s)
lower-body positive-pressure: By increasing the chamber in the lower body around Pressure acts as a counterweight to gravity
Study summary
A randomized controlled clinical study was conducted to elucidate the relationship between the lower extremity biomechanics of patients undergoing early gait training after ACLR surgery.The relationship between the biochemical characteristics of cartilage and the biomechanical risk index were proposed to providing exercise guidance and training for ACLR people and it is suggested that it can prevent and reduce the risk of cartilage degeneration early after operation.
Eligibility
Primary outcome measure(s)
- Gait biomechanical data — from 3 months to 2 years
Hip, knee and ankle joint angles and moments at the moment of landing and peak ground reaction force. - Gait biomechanical data — from 3 months to 2 years
The maximum three-dimensional torque of the hip, knee and ankle during the support phase. - Gait biomechanical data — from 3 months to 2 years
The maximum three-dimensional Angle and range of motion of the hip, knee and ankle joints during the whole gait cycle. - Gait biomechanical data — from 3 months to 2 years
The symmetry index of Angle and torque of each joint. - Gait biomechanical data — from 3 months to 2 years
The two groups of joint biomechanics and their gait touch information characteristics - Biochemical characteristics of knee cartilage — from 3 months to 2 years
T1rho values of different regions of knee cartilage - Biochemical characteristics of knee cartilage — from 3 months to 2 years
T2 mapping values of different regions of knee cartilage
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Peking University Third Hospital | Beijing | China | Recruiting |
More Peking University Third Hospital trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06368544 on ClinicalTrials.gov ↗ ← All trials in China